These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28179309)

  • 1. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
    Ishikura N; Yanagisawa M; Noguchi-Sasaki M; Iwai T; Yorozu K; Kurasawa M; Sugimoto M; Yamamoto K
    Anticancer Res; 2017 Feb; 37(2):623-629. PubMed ID: 28179309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
    Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L; Sørensen JB
    Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Ishikura N; Yorozu K; Kurasawa M; Yanagisawa M; Sugimoto M; Yamamoto K
    Oncol Rep; 2019 Sep; 42(3):1057-1065. PubMed ID: 31322247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of combination therapy modes of bevacizumab and paclitaxel for NSCLC in vivo.
    Wang J; Shen H; Jiang Q; Shu Y
    Pak J Pharm Sci; 2016 Mar; 29(2 Suppl):695-9. PubMed ID: 27113309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
    Barlesi F; Scherpereel A; Rittmeyer A; Pazzola A; Ferrer Tur N; Kim JH; Ahn MJ; Aerts JG; Gorbunova V; Vikström A; Wong EK; Perez-Moreno P; Mitchell L; Groen HJ
    J Clin Oncol; 2013 Aug; 31(24):3004-11. PubMed ID: 23835708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial.
    Galetta D; Cinieri S; Pisconti S; Gebbia V; Morabito A; Borsellino N; Maiello E; Febbraro A; Catino A; Rizzo P; Montrone M; Misino A; Logroscino A; Rizzi D; Di Maio M; Colucci G
    Clin Lung Cancer; 2015 Jul; 16(4):262-73. PubMed ID: 25582493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
    Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
    Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab Combined with Chemotherapy as First-line Therapy for Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
    Li F; Chen G; Jiao S
    Hepatogastroenterology; 2015 Jun; 62(140):797-801. PubMed ID: 26902004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma.
    Shen R; Li J; Ye D; Wang Q; Fei J
    Acta Biochim Biophys Sin (Shanghai); 2016 Oct; 48(10):894-901. PubMed ID: 27590062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
    Gautschi O; Mach N; Rothschild SI; Li Q; Stahel RA; Zippelius A; Cathomas R; Früh M; Betticher DC; Peters S; Rauch D; Feilchenfeldt J; Bubendorf L; Savic S; Jaggi R; Leibundgut EO; Largiadèr C; Brutsche M; Pilop C; Stalder L; Pless M; Ochsenbein AF;
    Clin Lung Cancer; 2015 Sep; 16(5):358-65. PubMed ID: 25843489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Patel JD; Bonomi P; Socinski MA; Govindan R; Hong S; Obasaju C; Pennella EJ; Girvan AC; Guba SC
    Clin Lung Cancer; 2009 Jul; 10(4):252-6. PubMed ID: 19632943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Spigel DR; Patel JD; Reynolds CH; Garon EB; Hermann RC; Govindan R; Olsen MR; Winfree KB; Chen J; Liu J; Guba SC; Socinski MA; Bonomi P
    J Thorac Oncol; 2015 Feb; 10(2):353-9. PubMed ID: 25611228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
    Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
    J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
    Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
    Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab.
    Zhao YY; Xue C; Jiang W; Zhao HY; Huang Y; Feenstra K; Resau JH; Qian CN; Zhang L
    J Thorac Oncol; 2012 Jan; 7(1):71-5. PubMed ID: 22011670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).
    Rittmeyer A; Gorbunova V; Vikström A; Scherpereel A; Kim JH; Ahn MJ; Chella A; Chouaid C; Campbell AK; Barlesi F
    J Thorac Oncol; 2013 Nov; 8(11):1409-16. PubMed ID: 24077452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.
    Kumar G; Woods B; Hess LM; Treat J; Boye ME; Bryden P; Winfree KB
    Lung Cancer; 2015 Sep; 89(3):294-300. PubMed ID: 26122345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.